secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-016796
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva updates RECOVER OLE enrollment: 358 enrolled, 23 completed 12 months, NDA on track for Q4 2025
--------------------------------------------------------------------------------

- 358 patients enrolled; 223 currently on treatment across USA, Europe, and Asia.
- 23 patients have completed 12 months of treatment; targeting 100 for NDA submission.
- Brilaroxazine generally well tolerated in acute and stable schizophrenia patients.
- Topline 12-month safety data expected in Q4 2024; NDA submission planned for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924016796/0001437749-24-016796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924016796/rvph20240514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer